Although some experimental evidence has implicated the TRAIL/TRAIL-receptor system in the regulation of osteoclastogenesis, the only available studies performed so far have been performed on isolated pre-osteoclasts, induced to differentiate by the addition of recombinant RANKL and M-CSF. Using a more physiological co-culture system in the absence of exogenous cytokines, we have here demonstrated that recombinant TRAIL inhibits osteoclast formation, but only at relatively high concentrations (500 ng/mL).
A number of studies have suggested a potential role of the tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) in modulating the differentiation of hematopoietic progenitors towards different lineages, including osteoclastogenesis (Secchiero et al., 2002; Secchiero et al., 2004; Zauli et al., 2004) . In particular, previous studies have shown that recombinant TRAIL either inhibits both human and mouse osteoclastogenesis when added to isolated preosteoclasts induced to differentiate with soluble recombinant macrophage colony stimulating factor (M-CSF) + receptor activator of NF-kB ligand (RANKL) (Zauli et al., 2004; Zauli et al., 2008) or induce apoptosis of mature osteoclasts (Roux et al., 2005 , Colucci et al. 2007 ). On the other hand, another study performed on peripheral blood cells purified from patients affected by multiple myeloma showed that the addition of recombinant TRAIL paradoxically induced osteoclastogenesis (Colucci et al., 2004) .The suggested mechanism proposed by Colucci et al. (2004) to explain the pro-osteoclastic activity of TRAIL was that TRAIL likely precluded osteoprotegerin (OPG) produced by the peripheral blood cells of patients affected by multiple myeloma from inhibiting the pro-osteoclastic activity of RANKL. In this respect, it has been recently shown that the affinity of OPG for native TRAIL was comparable to that for RANKL at 37°C, as determined by plasmon surface resonance analysis (Vitovski et al., 2007) . Moreover, in vitro studies have convincingly demonstrated that OPG acts in a paracrine or autocrine manner by binding TRAIL and promoting the survival of prostate cancer cells (Holen et al., 2002) and multiple myeloma cells (Shipman and Croucher, 2003) . Thus, the exact role of TRAIL in modulating osteoclastogenesis is uncertain.
In our opinion, the major limitation of these previous studies is that the effect of TRAIL was evaluated in culture systems in which isolated human peripheral blood mononuclear cells or the RAW264.7 macrophagic cell line were induced to differentiate into mature osteoclasts by the addition of recombinant RANKL+M-CSF. Since bone marrow stromal cells and osteoblasts are the major source of OPG within the bone marrow environment (Boyle et al., 2003) , to shed light into the role of TRAIL in osteoclastogenesis, we have analyzed the effect of increasing concentrations of recombinant human TRAIL, prepared as described (Zauli et al., 2003) , in a previously described model of co-cultures between mouse osteoblasts and RAW264.7 pre-osteoclastic cell line (Nicolin et al., 2006 ).This culture system shows the advantage that does not require the addition of exogenous cytokines, since it spontaneously produces both RANKL and OPG (Nicolin et al., 2006) . As shown in Figure 1 A, B , the addition of recombinant human TRAIL had no significant impact on the osteoclast formation up to 50 ng/mL. Only, at high concentrations (500 ng/mL), recombinant TRAIL significantly (p<0.05) inhibited the formation of osteoclasts. Although we are aware that mouse cells only express the homologue of human TRAIL-R2 while lacking the expression of TRAIL-R1, -R3, -R4 homologues (Zauli and Secchiero, 2006) and therefore experiments in mice cannot be immediately related to the human situation, our current observation, taken together with previous studies (Zauli et al., 2004; Zauli et al., 2008; Roux et al., 2005; Colucci et al., 2004; Colucci et al., 2007; Vitovski et al., 2007) indicate that the relative concentrations and the expression patterns of TRAIL and OPG in the local microenvironment are key determinant in the TRAIL/OPG interactions. Our findings also suggest that only at high but pharmacologically achievable concentrations (Cretney et al., 2007) ,TRAIL might efficiently inhibit osteoclastogenesis in vivo.
